DRAP Introduces Digital Licensing to Speed Up Approvals as part of its ongoing reforms to enhance efficiency in Pakistan’s healthcare sector. The Drug Regulatory Authority of Pakistan (DRAP) has implemented a digital approach to licensing, ensuring faster approval timelines. With this system, licensing processing time has reduced from years to just a few days, improving public access to medicines.
The DRAP digital licensing system allows companies to submit applications online, track their progress, and receive approvals without lengthy delays. DRAP Chief Executive Officer Dr Ubaidullah emphasized that these reforms have led to accelerated licensing timelines and streamlined approval procedures. Previously, manual processes caused long-standing delays, but the digitalization of licensing now ensures regulatory process improvement and greater transparency.
One major benefit of these reforms is the timely availability of essential medicines. Hospitals and pharmacies can now access drugs faster, while vaccine production in Pakistan is seeing improvements in quality and supply. DRAP is also supporting local vaccine manufacturing, working with international and provincial partners to stabilize healthcare supply chains and enhance self-reliance.
The authority’s focus on digital transformation strengthens the pharmaceutical regulatory authority’s role in Pakistan. The new online system reduces human errors, improves regulatory efficiency, and ensures wider access to medicines. Citizens and businesses alike benefit from a faster, more predictable licensing process.
In conclusion, DRAP’s digital licensing reforms mark a fundamental change in DRAP processes, making approvals faster, transparent, and more efficient. These efforts support better healthcare delivery, enhanced vaccine availability, and overall public health improvements.
Meta Description
DRAP introduces digital licensing to speed up approvals, reducing delays and improving access to essential medicines in Pakistan.
